From: Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
Status | Utility value | Comments |
---|---|---|
Remission | 0.799 [28] | |
Relapse | 0.670 [28] | |
Acute EPS (extra-pyramidal symptoms) | 0.7095 | Calculated by multiplying remission utility by expected decrement in utilities estimated in the NICE guidance [18] (0.888 for acute EPS and 0.959 for weight gain) |
Weight gain | 0.7662 | |
Diabetes Mellitus (controlled) | 0.760 [29] | |
Diabetes Mellitus complications | Disutility value [30] | |
Amputation | -0.109 | |
Fatal myocardial infarction | 1.000 | |
Heart failure | -0,108 | |
Ischaemic heart disease | -0.132 | |
Non-fatal myocardial infarction | -0.129 | |
Non-fatal Stroke | -0.181 |